MIRA
INFORM REPORT
|
Report Date : |
18th
November, 2006 |
IDENTIFICATION
DETAILS
|
Name : |
KUHNIL
PHARM. CO., LTD. |
|
|
|
|
Registered Office : |
297-5, Gunseo-ri, Jiksan-eup, Cheonan-si, Chungcheongnam-Do, Korea |
|
|
|
|
Country : |
Korea |
|
|
|
|
Financials (as on) : |
31.12.2005 |
|
|
|
|
Date of Incorporation : |
23.12.1955 |
|
|
|
|
Legal Form : |
Limited
Company |
|
|
|
|
Line of Business : |
Manufacture of
Medicinal Medicaments |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
Status : |
Satisfactory
|
|
|
|
|
Payment Behaviour : |
Regular
|
|
|
|
|
Litigation : |
Clear |
Basic
Information
|
Company Name |
KUHNIL PHARM. CO., LTD. |
|
Address |
297-5, Gunseo-ri, Jiksan-eup, Cheonan-si, CHUNGCHEONGNAM-DO, KOREA |
|
Building |
|
|
Zip Code |
330-811 |
|
Tel |
+82-41-580-5800 |
|
Fax |
+82-41-580-5807 |
|
E-mail |
kuhnil@kuhnil.com |
|
Website |
www.kuhnil.com |
|
Seoul Office |
237-12, Gongdeok 2-dong, Mapo-gu, SEOUL, KOREA |
|
Tel |
+82-2-714-0091 |
|
Fax |
+82-2-719-0493 |
|
Type |
Export/Import |
|
Industry |
Manufacture of
Medicinal Medicaments |
|
Main
Business |
The liver
Medicine For Promoting Nutrition, Gastritis Cure, Travail Antiphlogistic |
|
Sub Business |
|
|
Established |
12/23/1955 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Tetracycline(51101509) -Analgesics
Antiinflammatory Agents |
|
Sell |
Acetylcysteine(51161701) |
|
Sell |
Formulas and products for nutritional
support(42231800) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Dietary supplements and nutritional therapy
products(51191900) |
|
Sell |
Corticosteroids(51181700) |
|
Sell |
Antiulcer and related gastrointestinal GI
drugs(51171900) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
Others
|
Name |
Kim Young-Joong |
|
Address |
237, Myeongnyun-dong 2-ga, Jongno-gu, Seoul 110-767 Korea |
|
Date of Birth |
06/05/1969 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital |
4,600,000,000 KRW |
|
Employees |
359 |
|
Formation |
Co., Ltd., by shares |
The subject deals
with the companies in Japan, Singapore and Vietnam.
Management
|
Job
Description |
Title |
Name |
Sex |
Nationality |
Inauguration
Day |
|
President & CEO |
Mr. |
Kim Young-Joong |
Male |
Korean |
05/20/2005 |
|
Director |
Mr. |
Kim
Yong-Ok |
Male |
Korean |
05/20/2002 |
|
Director |
Mr. |
Kim
Sun-Soo |
Male |
Korean |
05/20/2002 |
|
Auditor |
Mr. |
Sun
Byung-Jin |
Male |
Korean |
11/02/1933 |
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
2005 |
64,990,841,633 |
62,214,016,597 |
3,596,441,520 |
|
2004 |
57,871,563,273 |
55,776,419,451 |
2,517,564,196 |
|
2003 |
|
|
|
|
2002 |
|
|
|
Financial Description
Unit: KRW
|
Authorized
Capital |
5,000,000,000 |
||
|
Paid-Up
Capital |
4,600,000,000 |
||
|
Total Issues Shares |
920,000 |
||
|
|
|||
|
Balance
Sheet Unit :
Korean Won |
|||
|
|
As
of 12/31/2005 |
As
of 12/31/2004 |
As
of 12/31/2003 |
|
Total Assets |
62,214,016,597 |
55,776,419,451 |
|
|
Current Assets |
38,294,163,566 |
35,568,898,672 |
|
|
-Quick
Assets |
27,995,212,787 |
27,986,413,858 |
|
|
-Inventories |
10,298,950,779 |
7,582,484,814 |
|
|
Fixed
Assets |
23,919,853,031 |
20,207,520,779 |
|
|
-Investment |
5,202,175,804 |
3,047,877,400 |
|
|
-Tangibles |
16,609,229,056 |
16,811,062,208 |
|
|
-Intangibles |
2,108,448,171 |
348,581,171 |
|
|
Total Liabilities |
18,384,668,757 |
15,543,513,131 |
|
|
Current Liabilities |
15,959,437,715 |
13,091,279,129 |
|
|
Fixed Liabilities |
2,425,231,042 |
2,452,234,002 |
|
|
Capital Stock |
4,600,000,000 |
4,600,000,000 |
|
|
Capital Surplus |
717,849,595 |
717,849,595 |
|
|
Profit Surplus |
38,511,498,245 |
34,915,056,725 |
|
|
Capital Adjustment |
- |
- |
|
|
Total Equity |
43,829,347,840 |
40,232,906,320 |
|
|
Liab. & Shareholder’s Equity |
62,214,016,597 |
55,776,419,451 |
|
|
|
|||
|
Income Statement Unit : Korean Won |
|||
|
|
As of 12/31/2005
|
As
of 12/31/2004 |
As
of 12/31/2003 |
|
Sales |
64,990,841,633 |
57,871,563,273 |
|
|
Cost of Sold Goods |
23,156,459,850 |
26,219,461,439 |
|
|
Gross Profit |
41,834,381,783 |
31,652,101,834 |
|
|
Selling
& Admin. Expenses |
34,640,035,317 |
26,525,608,080 |
|
|
Operating Income |
7,194,346,466 |
5,126,493,754 |
|
|
Non-Operating Income |
2,946,526,354 |
1,780,165,885 |
|
|
Non-Operating expenses |
1,238,384,140 |
1,138,406,193 |
|
|
Ordinary Income |
8,902,488,680 |
5,768,253,446 |
|
|
Special Income |
- |
- |
|
|
Income Before Taxes |
8,902,488,680 |
5,768,253,446 |
|
|
Income Taxes Expenses |
5,306,047,160 |
3,250,689,250 |
|
|
Net Income |
3,596,441,520 |
2,517,564,196 |
|
|
Bank Details |
Chohung Bank Shinchon Branch |
||
|
Corporate Registered
No. |
131111-0002011 |
||
|
Business Registered
No. |
312-81-06060 |
||
|
Permit &
Licenses |
|
||
|
Shareholder
Position |
Kim
Yong-Ok and his family have 99.00% of total shares. |
||
|
Company History |
12/23/1955
Established 04/14/1997
Changed company name to the present name |
||
Related Parties (Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
PENMIX Jongoh Pharmacy Sejin Building |
|
Cooperative Enterprise |
King Pharm.-USA Tedec Meiji-Spain Solco Basel AG-Swiss Schering Plough-USA Parke-Davis-USA Merril Dow-USA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|